Items Tagged ‘Stage II-IV Ovarian Cancer’

November 9th, 2016

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer

By

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to cancer progression for Lynparza-treated patients […]

View full entry

Tags: AstraZeneca, BRACAnalysis CDx, brca, lynparza, News, olaprarib, Ovarian Cancer, PARP enzyme, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


October 31st, 2016

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

By

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP […]

View full entry

Tags: BRCA1, BRCA2, lynparza, News, niraparib, olaparib, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


October 20th, 2016

Tesaro Provides Real Benefit to Ovarian Cancer Patients

By

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro improved cancer-free survival by 73% in patients with a BRCA mutation and by 55% in those without such mutations. The new data were presented at the […]

View full entry

Tags: 2016, BRCA mutation, ESMO, News, niraparib, Ovarian Cancer, parp, poly(ADP)-ribose polymerase, recurrent, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer, Tesaro


September 6th, 2016

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer

By

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated cancers. Rucaparib was granted Breakthrough Therapy Designation by the FDA in April 2015. About Ovarian Cancer […]

View full entry

Tags: Breakthrough Therapy Designation, News, Ovarian Cancer, PARP1, PARP2, PARP3, Stage II-IV Ovarian Cancer


August 22nd, 2016

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment

By

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed […]

View full entry

Tags: advanced, asco, cytoreductive surgery, epithelial, metastatic, NACT, News, Ovarian Cancer, SGO, Stage II-IV Ovarian Cancer


September 28th, 2015

Intraperitoneal Chemotherapy Underused in Ovarian Cancer

By

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer. These results were recently published in the Journal of Clinical Oncology. IP chemotherapy refers to chemotherapy that is delivered directly into the pelvis/abdominal area, […]

View full entry

Tags: intraperitoneal chemotherapy, IP, IV chemotherapy, News, Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


May 11th, 2015

Personalized Immunotherapy Delays Recurrence in Ovarian Cancer

By

A new immunotherapy known as Vigil™ may help delay the recurrence of advanced ovarian cancer. These findings were presented at the 2015 Annual Meeting on Women’s Cancer, March 28–31, in Chicago, Illinois. According to the American Cancer Society (ACS), ovarian cancer causes more deaths than any other cancer of the female reproductive system. The high […]

View full entry

Tags: News, Ovarian Cancer, personalized immunotherapy, Stage II-IV Ovarian Cancer, vigil


December 29th, 2014

Lynparza Approved in Advanced Ovarian Cancer

By

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes. According to statistics from the American Cancer Society (ACS), ovarian cancer causes more deaths than any other cancer of the female reproductive system. The ACS […]

View full entry

Tags: brca, lynparza, News, olaparib, Ovarian Cancer, parp, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


October 21st, 2014

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer

By

The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results of this study were recently reported in The Lancet Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than […]

View full entry

Tags: cedirnaib, News, olaparib, Ovarian Cancer, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


February 20th, 2014

Aspirin as Ovarian Cancer Prevention? Research Says Maybe

By

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk of several serious health issues. Studies have also found that an […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Screening/Prevention Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


January 30th, 2014

Dacogen Helps Recurrent Ovarian Cancer Respond to Vaccine

By

Treatment with Dacogen® (decitabine) prior to the administration of Adriamycin® (doxorubicin) and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, according to a study published in Cancer Immunology Research. Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading cause of cancer death among U.S. women, […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


September 18th, 2013

Dose-Dense Paclitaxel Plus Carboplatin Improves Long-Term Survival in Advanced Ovarian Cancer

By

Dose-dense paclitaxel plus carboplatin was associated with significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer, according to the results of a study published in the Lancet Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than […]

View full entry

Tags: News, Ovarian Cancer, Stage II-IV Ovarian Cancer


June 13th, 2013

Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer

By

In a Phase III clinical trial, treatment with Votrient® (pazopanib) after initial chemotherapy improved outcomes among women with advanced ovarian cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Ovarian cancer is often diagnosed at an advanced stage, highlighting the importance of finding new and more […]

View full entry

Tags: News, Ovarian Cancer, Stage II-IV Ovarian Cancer


April 12th, 2013

Delaying Chemotherapy Increases Mortality in Ovarian Cancer

By

Women with advanced ovarian cancer have significantly worse survival when they wait more than 25 days after surgery to start chemotherapy, according to the results of a study presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Los Angeles, California. Each year in the United States, roughly 22,000 women are […]

View full entry

Tags: News, Ovarian Cancer, Stage II-IV Ovarian Cancer


February 7th, 2013

Ovarian Cancer Rates Declining in Breast Cancer Survivors

By

The rate of second primary ovarian cancers after first primary breast cancer appears to be on the decline, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Overall incidence […]

View full entry

Tags: News, Ovarian Cancer, Recurrent Ovarian Cancer, Screening/Prevention Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer